Literature DB >> 22766642

Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.

Kiminori Kanno1, Shoji Kanno, Hiroyuki Nitta, Noriyuki Uesugi, Tamostu Sugai, Tomoyuki Masuda, Go Wakabayashi, Chihaya Maesawa.   

Abstract

Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that regulates many important biological processes, including cell migration, viral infection and autophagy. The aim of this study was to investigate the significance of HDAC6 in the invasion and metastasis activities of hepatocellular carcinoma (HCC). Three HCC cell lines and two primary cultures of hepatocytes were used for biological experiments. Immunohistochemistry for HDAC6 protein was also examined in 70 resected primary HCCs. Knockdown of the HDAC6 gene in the HCC cell lines was carried out by treatment with siRNA, and their migration and invasion activities were examined by the scratch assay and Matrigel invasion assay, respectively. HDAC6 expression was greater in all of the HCC cell lines compared to the primary cultures of hepatocytes. Knockdown of HDAC6 markedly downregulated the migration and invasion activities of all HCC cell lines (P<0.05). Overexpression of HDAC6 protein to a level higher than that in the corresponding normal hepatocytes was observed in 14 (20%) of the 70 primary HCCs, and was significantly correlated with high clinical stage, number of tumors, vascular invasion and intrahepatic metastasis (P<0.05). These results suggest that overexpression of the HDAC6 protein is involved in the migration and invasion activities of HCC cells, and may be a good biomarker for prediction of intrahepatic metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766642     DOI: 10.3892/or.2012.1898

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  32 in total

1.  Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.

Authors:  Chu Tang; Yang Du; Qian Liang; Zhen Cheng; Jie Tian
Journal:  Mol Imaging Biol       Date:  2020-06       Impact factor: 3.488

Review 2.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

3.  Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.

Authors:  Nicholas J Porter; Florence F Wagner; David W Christianson
Journal:  Biochemistry       Date:  2018-05-18       Impact factor: 3.162

Review 4.  Histone deacetylases as targets for treatment of multiple diseases.

Authors:  Jinhua Tang; Haidong Yan; Shougang Zhuang
Journal:  Clin Sci (Lond)       Date:  2013-06       Impact factor: 6.124

5.  Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.

Authors:  Lorena Rosik; Günter Niegisch; Ute Fischer; Manfred Jung; Wolfgang Arthur Schulz; Michèle Janine Hoffmann
Journal:  Cancer Biol Ther       Date:  2014-03-11       Impact factor: 4.742

6.  Histone deacetylase 6 is a FoxO transcription factor-dependent effector in skeletal muscle atrophy.

Authors:  Francesca Ratti; Francis Ramond; Vincent Moncollin; Thomas Simonet; Giulia Milan; Alexandre Méjat; Jean-Luc Thomas; Nathalie Streichenberger; Benoit Gilquin; Patrick Matthias; Saadi Khochbin; Marco Sandri; Laurent Schaeffer
Journal:  J Biol Chem       Date:  2014-12-15       Impact factor: 5.157

7.  HDAC6-mediated acetylation of lipid droplet-binding protein CIDEC regulates fat-induced lipid storage.

Authors:  Hui Qian; Yuanying Chen; Zongqian Nian; Lu Su; Haoyong Yu; Feng-Jung Chen; Xiuqin Zhang; Wenyi Xu; Linkang Zhou; Jiaming Liu; Jinhai Yu; Luxin Yu; Yan Gao; Hongchao Zhang; Haihong Zhang; Shimin Zhao; Li Yu; Rui-Ping Xiao; Yuqian Bao; Shaocong Hou; Pingping Li; Jiada Li; Haiteng Deng; Weiping Jia; Peng Li
Journal:  J Clin Invest       Date:  2017-03-13       Impact factor: 14.808

8.  Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.

Authors:  Gundula Streubel; Sabine Schrepfer; Hannah Kallus; Ulrike Parnitzke; Tanja Wulff; Frank Hermann; Matthias Borgmann; Svetlana Hamm
Journal:  Sci Rep       Date:  2021-05-05       Impact factor: 4.379

Review 9.  Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.

Authors:  Alexandria M Chan; Steven Fletcher
Journal:  RSC Med Chem       Date:  2020-12-11

Review 10.  HDAC6 and ovarian cancer.

Authors:  Joshua Haakenson; Xiaohong Zhang
Journal:  Int J Mol Sci       Date:  2013-05-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.